[go: up one dir, main page]

WO2004005466A3 - Methods and compositions for diagnosing hepatocellular carcinoma - Google Patents

Methods and compositions for diagnosing hepatocellular carcinoma Download PDF

Info

Publication number
WO2004005466A3
WO2004005466A3 PCT/US2003/020841 US0320841W WO2004005466A3 WO 2004005466 A3 WO2004005466 A3 WO 2004005466A3 US 0320841 W US0320841 W US 0320841W WO 2004005466 A3 WO2004005466 A3 WO 2004005466A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
hepatocellular carcinoma
compositions
hcc
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/020841
Other languages
French (fr)
Other versions
WO2004005466A2 (en
Inventor
Michael Katze
Roger Bumgarner
Maria Smit
Gary Rosenburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Illumigen Biosciences Inc
Original Assignee
Illumigen Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Illumigen Biosciences Inc filed Critical Illumigen Biosciences Inc
Priority to AT03763113T priority Critical patent/ATE493651T1/en
Priority to US10/520,322 priority patent/US7588902B2/en
Priority to JP2004519774A priority patent/JP4628098B2/en
Priority to AU2003247704A priority patent/AU2003247704A1/en
Priority to EP03763113A priority patent/EP1540342B1/en
Priority to DE60335553T priority patent/DE60335553D1/en
Publication of WO2004005466A2 publication Critical patent/WO2004005466A2/en
Publication of WO2004005466A3 publication Critical patent/WO2004005466A3/en
Anticipated expiration legal-status Critical
Priority to US12/538,055 priority patent/US20100172833A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Methods for the diagnosis of hepatocellular carcinoma (HCC) are set forth. Improved assay methods and scanning methods are included that employ non-cell-associated and cell-associated HCC related proteins. Such methods are based upon the discovery of genes that were up-regulated in diseased versus normal tissue as well as in HCC tissue when compared to the tissue of patients with other ailments.
PCT/US2003/020841 2002-07-03 2003-07-03 Methods and compositions for diagnosing hepatocellular carcinoma Ceased WO2004005466A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AT03763113T ATE493651T1 (en) 2002-07-03 2003-07-03 METHODS AND COMPOSITIONS FOR DIAGNOSING HEPA CELL CARCINOMA
US10/520,322 US7588902B2 (en) 2002-07-03 2003-07-03 Methods and compositions for diagnosing hepatocellular carcinoma
JP2004519774A JP4628098B2 (en) 2002-07-03 2003-07-03 Methods and compositions for diagnosing hepatocellular carcinoma
AU2003247704A AU2003247704A1 (en) 2002-07-03 2003-07-03 Methods and compositions for diagnosing hepatocellular carcinoma
EP03763113A EP1540342B1 (en) 2002-07-03 2003-07-03 Methods and compositions for diagnosing hepatocellular carcinoma
DE60335553T DE60335553D1 (en) 2002-07-03 2003-07-03 METHOD AND COMPOSITIONS FOR DIAGNOSIS OF A LIVER CELL CARCINOMA
US12/538,055 US20100172833A1 (en) 2002-07-03 2009-08-07 Methods and compositions for diagnosing hepatocellular carcinoma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39398202P 2002-07-03 2002-07-03
US60/393,982 2002-07-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/538,055 Continuation US20100172833A1 (en) 2002-07-03 2009-08-07 Methods and compositions for diagnosing hepatocellular carcinoma

Publications (2)

Publication Number Publication Date
WO2004005466A2 WO2004005466A2 (en) 2004-01-15
WO2004005466A3 true WO2004005466A3 (en) 2004-08-26

Family

ID=30115666

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/020841 Ceased WO2004005466A2 (en) 2002-07-03 2003-07-03 Methods and compositions for diagnosing hepatocellular carcinoma

Country Status (7)

Country Link
US (2) US7588902B2 (en)
EP (3) EP1540342B1 (en)
JP (2) JP4628098B2 (en)
AT (1) ATE493651T1 (en)
AU (1) AU2003247704A1 (en)
DE (1) DE60335553D1 (en)
WO (1) WO2004005466A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60335553D1 (en) 2002-07-03 2011-02-10 Illumigen Biosciences Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS OF A LIVER CELL CARCINOMA
EP2694088B1 (en) * 2011-04-07 2017-06-07 Efranat Ltd. Macrophage activating factor for pharmaceutical compositions
MX357018B (en) * 2013-12-18 2018-06-05 Instituto Nac De Medicina Genomica Method for the early diagnosis of hepatocellular carcinoma.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US393982A (en) 1888-12-04 jackson
JPS615800A (en) * 1984-06-20 1986-01-11 Sekisui Chem Co Ltd Determination of protein binding with vitamin d
JP2579497B2 (en) * 1987-09-07 1997-02-05 オリエンタル酵母工業株式会社 Liver disease diagnostic agent
US5641747A (en) * 1994-07-25 1997-06-24 Temple University-Of The Commonwealth System Of Higher Education Treatment of osteopetrotic diseases
US7368531B2 (en) * 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
EP0984984A2 (en) 1997-06-03 2000-03-15 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
US6552111B2 (en) 2000-12-22 2003-04-22 Eastman Kodak Company Cyclic olefin polymeric nanocomposite optical plastic article and method of making same
US20040068096A1 (en) 2001-09-21 2004-04-08 Zenta Tsuchihashi Human single nucleotide polymorphisms in organic anion transport and multi-drug resistant proteins
US20060046249A1 (en) 2002-01-18 2006-03-02 Fei Huang Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathways
WO2003083046A2 (en) 2002-03-08 2003-10-09 Curagen Corporation Novel proteins and nucleic acids encoding same
DE60335553D1 (en) 2002-07-03 2011-02-10 Illumigen Biosciences Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS OF A LIVER CELL CARCINOMA
US20070162394A1 (en) * 2004-02-12 2007-07-12 Iconix, Inc. Rapid identification of message authentication
US8296245B2 (en) * 2008-01-03 2012-10-23 Kount Inc. Method and system for creation and validation of anonymous digital credentials

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LIN ET AL: "Clinical aspects of hepatocellular carcinoma: role of serum C-reactive protein as a marker of hepatocellular carcinoma in patients with cirrhosis", J. OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 15, 2000, pages 417 - 421, XP002978059 *
SMITH ET AL: "Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma", CANCER RESEARCH, vol. 63, February 2003 (2003-02-01), pages 859 - 864, XP002978060 *
TAKAHASHI ET AL: "Expression of telomerase component genes in hepatocellular carcinoma", EUR. J. CANCER, vol. 36, March 2000 (2000-03-01), pages 496 - 502, XP001016326 *
TROJAN ET AL: "Fluorine-18 FDG position emission tomography for imaging of hepatocellular carcinoma", AM. J. GASTROENEROL., vol. 94, November 1999 (1999-11-01), pages 3314 - 3319, XP009058477 *

Also Published As

Publication number Publication date
AU2003247704A8 (en) 2004-01-23
EP1540342A4 (en) 2006-05-24
ATE493651T1 (en) 2011-01-15
EP2299268A2 (en) 2011-03-23
US20100172833A1 (en) 2010-07-08
JP2006508335A (en) 2006-03-09
US20070161058A1 (en) 2007-07-12
JP2011043512A (en) 2011-03-03
EP1540342B1 (en) 2010-12-29
EP2299268A3 (en) 2011-06-15
EP1540342A2 (en) 2005-06-15
DE60335553D1 (en) 2011-02-10
AU2003247704A1 (en) 2004-01-23
EP2293065A2 (en) 2011-03-09
US7588902B2 (en) 2009-09-15
JP4628098B2 (en) 2011-02-09
WO2004005466A2 (en) 2004-01-15
EP2293065A3 (en) 2011-06-15

Similar Documents

Publication Publication Date Title
WO2008057529A3 (en) Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp)
WO2006035237A3 (en) Methods and compositions relating to alzheimer's disease
NO20075046L (en) Gastroresistant pharmaceutical formulations containing rifaximin
WO2006033766A3 (en) Dendrimer based compositions and methods of using the same
WO2007007173A3 (en) Human anti-madcam antibodies
TR200103560T2 (en) Compositions for the diagnosis and treatment of breast cancer and their use
WO2004067023A3 (en) Survivin-derived peptides and use thereof
EP2182006A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004074434A3 (en) Methods and compositions for administering therapeutic and diagnostic agents
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2007038623A3 (en) Oral formulation for enteric disorders and/or rehydration
AU2002338852A1 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO2005079867A3 (en) Alpha-emitting hydroxyapatite particles
WO2004096159A3 (en) Saposin c-dops: a novel anti-tumor agent
WO2005054295A8 (en) Therapeutic and diagnostic anti-hsp 70 antibodies
WO2004104591A3 (en) Improvements to gamma delta t cell-mediated therapy
WO2004096124A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2006027693A8 (en) Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
WO2004005466A3 (en) Methods and compositions for diagnosing hepatocellular carcinoma
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
DE60322228D1 (en) FAST CRUMPING TABLET
WO2004003166A3 (en) Antibodies and uses thereof
EP2116616A3 (en) Genes differentially expressed in activated T cells and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004519774

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003763113

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003763113

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007161058

Country of ref document: US

Ref document number: 10520322

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10520322

Country of ref document: US